Progen gets in synth
Wednesday, 02 July, 2008
Brisbane biotech Progen Pharmaceuticals (ASX: PGL) has spun out its manufacturing business into a wholly-owned subsidiary.
The new subsidiary will be called PharmaSynth, and will be responsible for completing Progen's PI-88 manufacturing process.
It will also offer process development and manufacturing services to the biotechnology industry.
Progen's former director of manufacturing operations, Les Tillack, is the new company's CEO.
Liquid fat treatment provides hope for rare childhood disease
A liquid fat supplement, triheptanoin, can reverse mitochondrial dysfunction and cell death in...
NSW Govt delivers foot-and-mouth vaccine to protect livestock
A biodegradable vaccine to protect livestock from foot-and-mouth disease has been developed as...
Scientists optimise delivery of mRNA to target cells
A highly versatile new method captures and attaches antibodies to the surface of mRNA-loaded...
